Shattuck Labs, Inc.
STTK Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$5.54
KIRA · Stoqly’s AI analyst, in plain words
- Shattuck Labs, Inc. had $1.0M of revenue in fiscal 2025, down 82.5% on the year before. Over five years, revenue changed −36.8% a year on average.
- Its operating margin was −5,150.8%, down 3,742.5 pts: of every 100 in sales, about −5,151 is left after running the business.
- Shattuck Labs, Inc. lost $48.8M in fiscal 2025.
- Free cash flow was −$40.0M in fiscal 2025, −3,995.3% of revenue.
Market cap
$719M
P/E
—
Revenue
$1.0M
Net income
−$48.8M
Free cash flow
−$40.0M
Operating margin
−5,150.8%
Shattuck Labs, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−82.5%
No. Sales fell 82.5% last year.
Does it make a profit?
−4,880.9%
No. It lost money last year.
Does profit turn into cash?
−3,995.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Shattuck Labs, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- Shattuck Labs, Inc.
- CIK
- 0001680367
Shattuck Labs, Inc. · STTK
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $30.0M | $0.7M | $1.7M | $5.7M | $1.0M |
| Revenue growth | 202.2% | −97.8% | 154.1% | 245.3% | −82.5% |
| Operating margin | −150.8% | −15,848.0% | −5,549.6% | −1,408.3% | −5,150.8% |
| Net income | −$45.0M | −$102M | −$87.3M | −$75.4M | −$48.8M |
| Net margin | −149.8% | −15,635.7% | −5,268.4% | −1,318.1% | −4,880.9% |
| Diluted EPS | −$1.07 | −$2.41 | −$2.05 | −$1.49 | −$0.70 |
| Cash | |||||
| Cash from operations | −$57.1M | −$94.5M | −$81.2M | −$60.5M | −$39.9M |
| Capital expenditure | $7.9M | $11.6M | $0.4M | $0.1M | $0.1M |
| Free cash flow | −$65.0M | −$106M | −$81.6M | −$60.6M | −$40.0M |
| FCF margin | −216.7% | −16,274.8% | −4,926.7% | −1,058.8% | −3,995.3% |
| Share count change | 171.1% | 0.8% | 0.5% | 19.2% | 37.1% |
| Debt and strength | |||||
| Cash and short-term investments | $269M | $161M | $131M | $57.4M | $54.2M |
| Shareholders' equity | $272M | $176M | $145M | $79.6M | $82.4M |
| Current ratio | 11.7x | 7.4x | 12.5x | 8.9x | 11.7x |
| Returns and quality | |||||
| Return on equity | −15.5% | −45.5% | −54.4% | −67.2% | −60.3% |
| Return on tangible equity | −16.5% | −57.9% | −60.3% | −94.7% | −59.2% |
| Piotroski F-score | 1 | 1 | 3 | 2 | 3 |
| Altman Z'' | 14.1 | 4.6 | 5.5 | −7.2 | −3.8 |
Insiders bought, 12 months
$0.3M
1 insider
Insiders sold, 12 months
$0.6M
2 insiders
Of sales under plans
100%
$0.6M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Shattuck Labs, Inc. · STTK
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $5.54 a share, the company is worth $719M.
Source: SEC EDGAR XBRL filings (CIK 0001680367). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.